Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX108-A Tablets in Advanced Colorectal Cancer (Phase II)
CTR20260497Phase 2Active
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RX108 in colorectal cancer (CRC), sponsored by Suzhou Runxin Biotechnology. Started Feb 2026; status: active.
02
Drugs
RX108
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260497.